Marken taps into innovations to smooth clinical trial supply chain

By Maggie Lynch contact

- Last updated on GMT

Related tags: Marken, Supply chain, Clinical research, Clinical supply, Clinical trial, Packaging

Marken executive says there is no such thing as a perfect clinical trial supply chain but with strategic planning and innovations there are opportunities to better serve the research industry.

Marken’s direct-to-patient services create a supply chain that can bring the medicine directly to the patient instead of directly to the site, and Dan Bell, VP of North American Operations and Global Regulatory Affairs, said this can improve trial compliance simply out of convenience – enabling clinical trial participants to reduce the need to visit trial sites and clinic.

Innovations in packaging for clinical supply are additional areas Marken is looking into. “We’ve done a lot of work on what we call thermo-isolating, better packaging that’s lighter and that can keep things at the right temperature longer – there’s constant innovation there,” ​said Bell.

Currently, Marken’s supply chain uses controlled room temperature facilities, refrigerators and freezers, and packaging materials with GPS and remote temperature monitoring devices, to provide cold chain, ultra-cold chain, and ambient temperature shipping for both its direct-to-patient services and its traditional supply chain.

He added that beyond the innovations that can enable remote temperature readings and GPS tracking that it is currently using, software systems that use artificial intelligence (AI) can pose the opportunity to design an accelerated supply chain by tapping into big data.  

For a look inside Marken’s Chicago facility, and to hear more about the work the company is doing to innovate, catch our quick video above.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars